jueves, 16 de noviembre de 2017

FDA approves sunitinib malate for adjuvant treatment of renal cell carcinoma

U.S. Food and Drug Administration Header

FDA approves sunitinib malate for adjuvant treatment of renal cell carcinoma


    FDA approved sunitinib malate (Sutent, Pfizer Inc.) for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy. More Information.  November 16, 2017

    Other Hematology/Oncology (Cancer) Approvals & Safety Notifications

    No hay comentarios:

    Publicar un comentario